Both the CheckMate-901 (gemcitabine-cisplatin plus nivolumab) trial and the EV-302 (enfortumab-vedotin plus pembrolizumab; EV+P) trial have shown a significant improvement in OS over standard (cis)platinum-based chemotherapy. The effect size, as well as the broader eligibility criteria for EV+P position this regimen as a compelling preferred candidate for the new standard of care in front-line mUC treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euf.2024.06.003 | DOI Listing |
Publication Analysis
Top Keywords
advancements front-line
4
front-line treatment
4
treatment metastatic
4
metastatic urothelial
4
urothelial carcinoma
4
carcinoma checkmate-901
4
checkmate-901 gemcitabine-cisplatin
4
gemcitabine-cisplatin nivolumab
4
nivolumab trial
4
trial ev-302
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!